RenSuper Biologics: Empowering Next-Generation Dual Payload ADCs with AI-Driven Precision & Scalability
12:30 pm - Tuesday 13th October 2026
- Leveraging the RenLite common light chain to eliminate mismatching and ensure high homogeneity and "antibody-like" stability for dual payload formats
- Combining two distinct, complementary MoAs on a single molecule to tackle tumor heterogeneity and bypass resistance
- Spotlighting RenSuper Workstation AI Platform, scanning 200+ TAA targets and 100,000s of ready-to-go antibodies to match the ideal lead with optimal internalization in record time
